» Articles » PMID: 39600566

Raising the Bar in Ulcerative Colitis Management

Abstract

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by growing incidence and prevalence around the world in the last few decades. The range of available existing treatment and strategies for its management is being implemented. Given the introduction of newly developed molecules and the lack of specific guidelines, drug positioning may represent a tough clinical challenge. UC management is mostly medical, and it has been shifting toward a more personalized approach with the aim to create a tailored strategy depending on the patient's profile. A treat-to target strategy seems to be the best approach to reach disease control as it allows to carry out therapeutic choices based on objective and specific parameters: histological, ultrasonographic, and molecular targets may add to the already used clinical, endoscopic, and biochemical targets. In addition, dual-targeted therapy has emerged as an attractive therapeutic strategy for patients not achieving remission. This review aims to provide an overview of the available strategies to raise the bar in UC.

Citing Articles

Dual Therapy in Inflammatory Bowel Disease.

Altieri G, Zilli A, Parigi T, Allocca M, Furfaro F, Fiorino G Biomolecules. 2025; 15(2).

PMID: 40001525 PMC: 11853240. DOI: 10.3390/biom15020222.

References
1.
Adedokun O, Xu Z, Gasink C, Kowalski K, Sandborn W, Feagan B . Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease. Clin Ther. 2022; 44(10):1336-1355. DOI: 10.1016/j.clinthera.2022.08.010. View

2.
Danese S, Ferrante M, Feagan B, Peyrin-Biroulet L, Hibi T, Sandborn W . Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial. Am J Gastroenterol. 2022; 118(1):138-147. PMC: 9810009. DOI: 10.14309/ajg.0000000000001979. View

3.
Agrawal M, Kim E, Colombel J . JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications. J Crohns Colitis. 2020; 14(Supplement_2):S755-S760. PMC: 7395307. DOI: 10.1093/ecco-jcc/jjaa017. View

4.
Stamatiades G, Ioannou P, Petrikkos G, Tsioutis C . Fungal infections in patients with inflammatory bowel disease: A systematic review. Mycoses. 2018; 61(6):366-376. PMC: 5980782. DOI: 10.1111/myc.12753. View

5.
Solitano V, Facciorusso A, Jess T, Ma C, Hassan C, Repici A . Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2022; 21(4):907-921.e2. DOI: 10.1016/j.cgh.2022.07.032. View